MRT-2359
Monte Rosa Therapeutics
[]
$glue monte rosa therapeutics presents preclinical data from gspt1 degrader program focused on myc-driven cancers at aacr 2023 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities